

Figure S1



Hsu et al., 2011

A



LNCaP

22Rv1



AR





Cdk5





Merge



DAPI



Phase



B






Figure S2

Hsu et al., 2011


A



B



C



D





Figure S3

Hsu et al., 2011

A

siRNA-control



B

pEGFP-Cdk5





Figure S3

Hsu et al., 2011

C



D






Figure S4

Hsu et al., 2011

A





B



EGFP

Cdk5

anti-
AR



anti-
Cdk5




Xenografted tumors

Figure S5


Hsu et al., 2011

Negative (0) Low (1) Moderate (2) High (3)

AR



Cdk5



p35

